Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AURKA | O14965 | 10/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 5/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MAPT | P10636 | 4/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.51 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4771087 | 0.95 | AURKA (0.58) | AURKATP53MEN1KMT2AMAPT | |
| Trifluoroacetic Acid SCHEMBL4771910 | 0.91 | AURKA (0.52) | AURKATP53MEN1KMT2AMAPT | |
| SCHEMBL4773081 | 0.86 | AURKA (0.56) | AURKATP53MEN1KMT2AMAPT | |
| Trifluoroacetic Acid SCHEMBL4765546 | 0.83 | MEN1 (0.53) | TP53MEN1KMT2AMAPTSMN1; SMN2 | |
| Trifluoroacetic Acid SCHEMBL4765255 | 0.82 | SLC2A1 (0.43) | TP53ALDH1A1LMNASMN1; SMN2RAB9A | |
| Trifluoroacetic Acid SCHEMBL4770781 | 0.80 | SLC2A1 (0.42) | AURKA | |
| Trifluoroacetic Acid SCHEMBL4765765 | 0.80 | TP53 (0.50) | TP53MEN1KMT2AMAPTLMNA | |
| Trifluoroacetic Acid SCHEMBL4774158 | 0.78 | TMPRSS2 (0.55) | TP53MEN1KMT2AMAPTALDH1A1 | |
| Trifluoroacetic Acid SCHEMBL4775487 | 0.78 | KMT2A (0.53) | MEN1KMT2AALDH1A1KDM4ELMNA | |
| Trifluoroacetic Acid SCHEMBL4774586 | 0.78 | MAPT (0.51) | KMT2AMAPTALDH1A1LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | claimed |
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | GLAXO GROUP LIMITED (GB) | 2007-03-15 | — | — | US | claimed |
| EP-1713778-B1 | BENZAZEPINE DERIVATIVES AS HISTAMINE H3 ANTAGONISTS | GLAXO GROUP LTD (GB) | 2008-01-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070060566-A1 | Benzazepine derivatives as histamine h3 antagonists | HRH3, HRH4, HRH1 | AURKA 1133/4885TP53 4863/4885MEN1 2213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.